|
Persistent Identifier
|
perma:LIST.BM7J2B |
|
Publication Date
|
2026-07-06 |
|
Title
| Glioblastoma-instructed microglia transition to heterogeneous phenotypic states with phagocytic and dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts [* Cross-Reference *] |
|
Other Identifier
| https://doi.org/10.1186/s13073-024-01321-8
OpenAlex ID: https://openalex.org/W4393412071 |
|
Author
| Yahaya A Yabo (University of Luxembourg, Luxembourg Institute of Health) - ORCID: https://orcid.org/0000-0002-1128-6038
Pilar M. Moreno‐Sanchez (University of Luxembourg, Luxembourg Institute of Health) - ORCID: https://orcid.org/0000-0002-1479-8039
Yolanda Pires‐Afonso (University of Luxembourg, Luxembourg Institute of Health) - ORCID: https://orcid.org/0000-0002-5773-414X
Tony Kaoma (Luxembourg Institute of Health) - ORCID: https://orcid.org/0000-0002-1269-4826
Bakhtiyor Nosirov (Luxembourg Institute of Health) - ORCID: https://orcid.org/0000-0002-4644-2758
Andrea Scafidi (University of Luxembourg, Luxembourg Institute of Health) - ORCID: https://orcid.org/0000-0002-3089-2439
Luca Ermini (Luxembourg Institute of Health) - ORCID: https://orcid.org/0000-0001-8109-6021
Anuja Lipsa (Luxembourg Institute of Health) - ORCID: https://orcid.org/0000-0002-9668-6048
Anaïs Oudin (Luxembourg Institute of Health) - ORCID: https://orcid.org/0000-0001-5552-9823
Dimitrios Kyriakis (University of Luxembourg) - ORCID: https://orcid.org/0000-0003-1643-2310
Kamil Grzyb (University of Luxembourg) - ORCID: https://orcid.org/0000-0002-2416-9500
Suresh Poovathingal (University of Luxembourg, Vlaams Instituut voor Biotechnologie) - ORCID: https://orcid.org/0000-0002-3236-2255
Aurélie Poli (Luxembourg Institute of Health) - ORCID: https://orcid.org/0000-0002-7986-0761
Arnaud Muller (Luxembourg Institute of Health) - ORCID: https://orcid.org/0000-0002-3841-4722
Réka Tóth (Luxembourg Institute of Health) - ORCID: https://orcid.org/0000-0002-6096-1052
Barbara Klink (German Cancer Research Center, Heidelberg University, Luxembourg Institute of Health, National Center for Tumor Diseases, Laboratoire National de Santé, University Hospital Carl Gustav Carus, Technische Universität Dresden) - ORCID: https://orcid.org/0000-0002-8753-8238
Guy Berchem (Centre Hospitalier de Luxembourg, University of Luxembourg, Luxembourg Institute of Health) - ORCID: https://orcid.org/0000-0003-0157-2257
C. Berthold (Centre Hospitalier de Luxembourg)
Frank Hertel (Centre Hospitalier de Luxembourg)
Michel Mittelbronn (University of Luxembourg, Luxembourg Institute of Health, Laboratoire National de Santé) - ORCID: https://orcid.org/0000-0002-2998-052X
Dieter Henrik Heiland (Northwestern University, University of Freiburg, German Cancer Research Center, Friedrich-Alexander-Universität Erlangen-Nürnberg, University Medical Center Freiburg, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen, Neurological Surgery) - ORCID: https://orcid.org/0000-0002-9258-3033
Alexander Skupin (University of Luxembourg, University of California San Diego, Luxembourg Institute of Science and Technology) - ORCID: https://orcid.org/0000-0002-8955-8304
Petr V. Nazarov (Luxembourg Institute of Health) - ORCID: https://orcid.org/0000-0003-3443-0298
Simone P. Niclou (University of Luxembourg, Luxembourg Institute of Health) - ORCID: https://orcid.org/0000-0002-3417-9534
Alessandro Michelucci (University of Luxembourg, Luxembourg Institute of Health) - ORCID: https://orcid.org/0000-0003-1230-061X
Anna Golebiewska (Luxembourg Institute of Health) - ORCID: https://orcid.org/0000-0002-4160-2521 |
|
Point of Contact
|
Use email button above to contact.
LIST QDKM (LIST) |
|
Description
| Background: A major contributing factor to glioblastoma (GBM) development and progression is its ability to evade the immune system by creating an immune-suppressive environment, where GBM-associated myeloid cells, including resident microglia and peripheral monocyte-derived macrophages, play critical pro-tumoral roles. However, it is unclear whether recruited myeloid cells are phenotypically and functionally identical in GBM patients and whether this heterogeneity is recapitulated in patient-derived orthotopic xenografts (PDOXs). A thorough understanding of the GBM ecosystem and its recapitulation in preclinical models is currently missing, leading to inaccurate results and failures of clinical trials. Methods: Here, we report systematic characterization of the tumor microenvironment (TME) in GBM PDOXs and patient tumors at the single-cell and spatial levels. We applied single-cell RNA sequencing, spatial transcriptomics, multicolor flow cytometry, immunohistochemistry, and functional studies to examine the heterogeneous TME instructed by GBM cells. GBM PDOXs representing different tumor phenotypes were compared to glioma mouse GL261 syngeneic model and patient tumors. Results: We show that GBM tumor cells reciprocally interact with host cells to create a GBM patient-specific TME in PDOXs. We detected the most prominent transcriptomic adaptations in myeloid cells, with brain-resident microglia representing the main population in the cellular tumor, while peripheral-derived myeloid cells infiltrated the brain at sites of blood–brain barrier disruption. More specifically, we show that GBM-educated microglia undergo transition to diverse phenotypic states across distinct GBM landscapes and tumor niches. GBM-educated microglia subsets display phagocytic and dendritic cell-like gene expression programs. Additionally, we found novel microglial states expressing cell cycle programs, astrocytic or endothelial markers. Lastly, we show that temozolomide treatment leads to transcriptomic plasticity and altered crosstalk between GBM tumor cells and adjacent TME components. Conclusions: Our data provide novel insights into the phenotypic adaptation of the heterogeneous TME instructed by GBM tumors. We show the key role of microglial phenotypic states in supporting GBM tumor growth and response to treatment. Our data place PDOXs as relevant models to assess the functionality of the TME and changes in the GBM ecosystem upon treatment. Graphical Abstract: (Figure presented.) (2024-04-02)
***This entry has been automatically imported via OpenAlex by LIST harvest scripts. Please refer to https://doi.org/10.1186/s13073-024-01321-8 for the original and latest version of the publication*** (2026-07-01) |
|
Subject
| Medicine, Health and Life Sciences |
|
Keyword
| Microglia
Tumor microenvironment
Myeloid
Glioma
Phenotype
Immune system
Brain tumor
Cancer research
Transcriptome
Biology
Population
Cell
Immunology
Medicine
Pathology
Inflammation
Gene expression
Gene
Genetics |
|
Topic Classification
| Glioma Diagnosis and Treatment
Immune cells in cancer
Neuroinflammation and Neurodegeneration Mechanisms |
|
Deposit Date
| 2024-04-02 |
|
Data Type
| Article |
|
Data Source
| Genome Medicine |